Call Us Today
Schedule Your Consultation
or email us

Thursday, October 19, 2017

Risperdal Lawsuits Escalate in 2017!

Risperdal an anti-psychotic drug was approved by the FDA in 1993 for treatment of schizophrenia, bipolar mania, and autism. However, one of the serious side effects of the drug is gynecomastia or the development of female type breasts in men and boys.

Risperdal Sales Have Exceeded $30 Billion

Thousands of lawsuits have been filed against Johnson and Johnson because they hid the fact that gynecomastia could result from the drug. In addition, Johnson and Johnson has been accused of practicing illegal marketing ploys such as paying kickbacks to physicians for prescribing Risperdal. To date, the sales of Risperdal have exceeded $30 billion worldwide.

More than 3,000 new Risperdal lawsuits have been filed in the first quarter of 2017, bringing the total to approximately 20,000 for the U.S. and Canada.

A Claimant Was Awarded $77 Million!

Last year a Risperdal claimant received a record-setting verdict award of $70million with an additional $7 million added by the judge for delay damages. The tolling agreement on thousands of cases was canceled by Johnson and Johnson, which pauses the statute of limitations deadline. With no expiration date for filing a lawsuit, the courts will be overburdened. Either side retains the right to cancel the agreement.

Of the 8 cases that have gone to trial in Philadelphia, 4 verdicts went in favor of the plaintiffs and 4 in favor of Johnson and Johnson, but appeals are still pending in the state’s Superior Court.

With large awards being handed down, TV ads are prolific in search of more claimants. In 2016 there were over 3,800 TV.

36 states have now filed lawsuits against Janssen, a subsidiary of Johnson and Johnson and the manufacturer of Risperdal.

To date, the drug is still being prescribed by doctors. 

Call Today!

If you are having any issues with gynecomastia, call now (415) 898-4161 for a consultation with Dr. Miguel Delgado, M.D.